Oxford BioDynamics PLC
Company Profile
Business description
Oxford BioDynamics PLC is a biotechnology company engaged in developing and commercializing precision clinical diagnostic tests for life-changing diseases. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The tests are based on the company's proprietary 3D genomic biomarker platform, EpiSwitch which enables screening, evaluation, validation, and monitoring of biomarkers. In addition, the company offers, EpiSwitch Explorer Array Kit for 3D genome profiling. It is also developing new tests in the areas of oncology, neurology, inflammation, hepatology, and animal health. Geographically, it derives key revenue from the United States of America.
Contact
John Smith Drive
3140 Rowan Place, ARC Oxford
OxfordOX4 2WB
GBRT: +44 1865518910
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 September 2026
Employees
44
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% |
| CAC 40 | 8,160.51 | 40.37 | -0.49% |
| DAX 40 | 24,085.79 | 33.10 | -0.14% |
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% |
| FTSE 100 | 9,743.27 | 16.79 | -0.17% |
| HKSE | 25,956.24 | 326.45 | -1.24% |
| NASDAQ | 23,581.14 | 377.33 | -1.57% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% |
| S&P 500 | 6,822.34 | 68.25 | -0.99% |
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% |
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |